Generic and biosimilar drugmaker Sandoz has agreed to pay $265 million to settle allegations of price-fixing in a Pennsylvania lawsuit.

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company.

Get the latest Sandoz Group AG (SDZNY) stock news and headlines to help you in your trading and investing decisions.